429 related articles for article (PubMed ID: 15126001)
1. Prostaglandin E1 in lipid microspheres ameliorates diabetic peripheral neuropathy: clinical usefulness of Semmes-Weinstein monofilaments for evaluating diabetic sensory abnormality.
Akahori H; Takamura T; Hayakawa T; Ando H; Yamashita H; Kobayashi K
Diabetes Res Clin Pract; 2004 Jun; 64(3):153-9. PubMed ID: 15126001
[TBL] [Abstract][Full Text] [Related]
2. Prostaglandin E1 incorporated in lipid microspheres in the treatment of peripheral vascular diseases and diabetic neuropathy.
Hoshi K; Mizushima Y; Kiyokawa S; Yanagawa A
Drugs Exp Clin Res; 1986; 12(8):681-5. PubMed ID: 3757764
[TBL] [Abstract][Full Text] [Related]
3. Lipo-PGE1, a new lipid-encapsulated preparation of prostaglandin E1: placebo-and prostaglandin E1-controlled multicenter trials in patients with diabetic neuropathy and leg ulcers.
Toyota T; Hirata Y; Ikeda Y; Matsuoka K; Sakuma A; Mizushima Y
Prostaglandins; 1993 Nov; 46(5):453-68. PubMed ID: 8278621
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of different doses of lipo-prostaglandin E1 in the treatment of painful diabetic peripheral neuropathy.
Hong L; Zhang J; Shen J
J Diabetes Complications; 2015; 29(8):1283-6. PubMed ID: 26355026
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Semmes-Weinstein monofilament examination for diabetic peripheral neuropathy screening.
Kamei N; Yamane K; Nakanishi S; Yamashita Y; Tamura T; Ohshita K; Watanabe H; Fujikawa R; Okubo M; Kohno N
J Diabetes Complications; 2005; 19(1):47-53. PubMed ID: 15642490
[TBL] [Abstract][Full Text] [Related]
6. PGE1 improves diabetic peripheral neuropathy in patients with type 2 diabetes.
Wu JD; Tao S; Jin X; Jiang LL; Shen Y; Luo Y; Zhang P; Lee KO; Ye L; Ma JH
Prostaglandins Other Lipid Mediat; 2016 Nov; 126():24-28. PubMed ID: 27421690
[TBL] [Abstract][Full Text] [Related]
7. A multicenter double blind controlled study of lipo-PGE1, PGE1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders.
Mizushima Y; Shiokawa Y; Homma M; Kashiwazaki S; Ichikawa Y; Hashimoto H; Sakuma A
J Rheumatol; 1987 Feb; 14(1):97-101. PubMed ID: 3553591
[TBL] [Abstract][Full Text] [Related]
8. [Clinical observation of combined therapeutic effect of prostaglandin E1 and mecobalamin on diabetic peripheral neuropathy].
Zhu XP; Zhou ZG
Hunan Yi Ke Da Xue Xue Bao; 2001 Aug; 26(4):343-4. PubMed ID: 12536730
[TBL] [Abstract][Full Text] [Related]
9. Effects of a single drip infusion of lipo-prostaglandin E1 on vibratory threshold in patients with diabetic neuropathy.
Tawata M; Nitta K; Kurihara A; Nagasaka T; Iwase E; Gan N; Inoue M; Onaya T
Prostaglandins; 1995 Jan; 49(1):27-39. PubMed ID: 7792389
[TBL] [Abstract][Full Text] [Related]
10. Treatment of established collagen induced arthritis with prostaglandin E1 incorporated in lipid microspheres.
Moriuchi-Murakami E; Yamada H; Ishii O; Kikukawa T; Igarashi R
J Rheumatol; 2000 Oct; 27(10):2389-96. PubMed ID: 11036835
[TBL] [Abstract][Full Text] [Related]
11. Lipo-prostaglandin E1 in combination with steroid therapy is effective for treatment of sudden sensorineural hearing loss in Korean patients with Type 2 diabetes.
Ahn JH; Kim TY; Kim YJ; Han MW; Yoon TH; Chung JW
Diabet Med; 2006 Dec; 23(12):1339-43. PubMed ID: 17116185
[TBL] [Abstract][Full Text] [Related]
12. Hemodynamic effects of lipo-PGE1 on peripheral artery in patients with diabetic neuropathy: evaluated by two-dimensional color Doppler echography.
Okuda Y; Mizutani M; Ogawa M; Sone H; Asano M; Tsurushima Y; Morishima Y; Asakura Y; Suzuki S; Isaka M
Diabetes Res; 1993; 22(2):87-95. PubMed ID: 8205741
[TBL] [Abstract][Full Text] [Related]
13. Clinical usefulness of the two-site Semmes-Weinstein monofilament test for detecting diabetic peripheral neuropathy.
Lee S; Kim H; Choi S; Park Y; Kim Y; Cho B
J Korean Med Sci; 2003 Feb; 18(1):103-7. PubMed ID: 12589096
[TBL] [Abstract][Full Text] [Related]
14. Does anodyne light therapy improve peripheral neuropathy in diabetes? A double-blind, sham-controlled, randomized trial to evaluate monochromatic infrared photoenergy.
Lavery LA; Murdoch DP; Williams J; Lavery DC
Diabetes Care; 2008 Feb; 31(2):316-21. PubMed ID: 17977931
[TBL] [Abstract][Full Text] [Related]
15. Use of the C64 quantitative tuning fork and the effect of niceritrol in diabetic neuropathy.
Hotta N; Sugimura K; Tsuchida I; Sano T; Koh N; Matsumae H; Sakamoto N
Clin Ther; 1994; 16(6):1007-15. PubMed ID: 7697680
[TBL] [Abstract][Full Text] [Related]
16. Assessment of sensory neuropathy in diabetic patients without diabetic foot problems.
Nather A; Neo SH; Chionh SB; Liew SC; Sim EY; Chew JL
J Diabetes Complications; 2008; 22(2):126-31. PubMed ID: 18280443
[TBL] [Abstract][Full Text] [Related]
17. Prostaglandin E1 incorporated in lipid microspheres (lipo PGE1).
Otomo S; Mizushima Y; Aihara H; Yokoyama K; Watanabe M; Yanagawa A
Drugs Exp Clin Res; 1985; 11(9):627-31. PubMed ID: 3880049
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the effect of Lipo PGE1 and other related compounds on experimental peripheral arterial occlusive disease in rats.
Goto J; Araki H; Otomo S; Aihara H
Drugs Exp Clin Res; 1986; 12(11):917-21. PubMed ID: 3816509
[TBL] [Abstract][Full Text] [Related]
19. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy.
Ekberg K; Brismar T; Johansson BL; Lindström P; Juntti-Berggren L; Norrby A; Berne C; Arnqvist HJ; Bolinder J; Wahren J
Diabetes Care; 2007 Jan; 30(1):71-6. PubMed ID: 17192336
[TBL] [Abstract][Full Text] [Related]
20. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy.
Bastyr EJ; Price KL; Bril V;
Clin Ther; 2005 Aug; 27(8):1278-94. PubMed ID: 16199253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
